重症肺炎患者免疫调节治疗的研究进展
Research Advances in Immune Modulation Therapy for Patients with Severe Pneumonia
DOI: 10.12677/acm.2025.1582224, PDF,   
作者: 温 飞*:延安大学医学院,陕西 延安;王国芳:延安大学附属医院呼吸与危重症科,陕西 延安
关键词: 重症肺炎免疫调节治疗发病机制Severe Pneumonia Immune Modulation Therapy Pathogenesis
摘要: 免疫功能在重症肺炎的发病过程以及疾病的发展过程中起着非常关键的作用,免疫过度激活或免疫抑制状态,均可能对患者的临床结局产生不利影响。临床上,免疫调节疗法已经广泛应用于感染、肿瘤、自身免疫性疾病等多种疾病,尤其在重症肺炎、免疫相关不良反应及慢性炎症性疾病中作用突出。重症肺炎病情危重,易伴发多器官功能障碍,近些年来,传统抗感染联合免疫调节治疗策略正向精准化方向发展。本文在阅读文献的前提下旨在梳理关于重症肺炎患者免疫调节机制、免疫细胞重编码、肺炎疫苗研发以及治疗方面的一些关键突破以及进展,以期为未来的临床工作提供有价值的参考。
Abstract: Immune function plays a pivotal role in both the pathogenesis and progression of severe pneumonia. Both immune hyperactivation and immunosuppression can adversely impact patient clinical outcomes. Clinically, immunomodulatory therapies are now widely applied across various diseases, including infections, malignancies, and autoimmune disorders, demonstrating particularly significant efficacy in severe pneumonia, immune-related adverse events (irAEs), and chronic inflammatory diseases. Severe pneumonia is characterized by its critical condition and frequent association with multi-organ dysfunction syndrome (MODS). In recent years, the traditional approach of combining antimicrobials with immunomodulation is evolving toward precision-based approaches. Based on a review of the current literature, this article aims to synthesize key breakthroughs and recent advances in understanding immunomodulatory mechanisms, immune cell reprogramming, pneumonia vaccine development, and therapeutic strategies for patients with severe pneumonia. The goal is to provide valuable insights for future clinical practice.
文章引用:温飞, 王国芳. 重症肺炎患者免疫调节治疗的研究进展[J]. 临床医学进展, 2025, 15(8): 226-230. https://doi.org/10.12677/acm.2025.1582224

参考文献

[1] Oxford Centre for Evidence-Based Medicine (2011) The Oxford 2011 Levels of Evidence. OCEBM.
https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
[2] 中国医师协会急诊医师分会, 中国急诊专科医联体, 北京急诊医学学会. 急诊成人社区获得性肺炎临床实践指南(2024年版) [J]. 中华急诊医学杂志, 2025, 34(3): 300-317.
[3] Rothberg, M.B. (2022) Community-Acquired Pneumonia. Annals of Internal Medicine, 175, ITC49-ITC64. [Google Scholar] [CrossRef] [PubMed]
[4] Guo, H., Zhao, X., Han, K. and Wang, Y. (2025) Mapping the Lung-Brain Axis: Causal Relationships between Brain Network Connectivity and Respiratory Disorders. Brain Research Bulletin, 227, Article ID: 111402. [Google Scholar] [CrossRef] [PubMed]
[5] Li, W., Zhu, H., Zou, X., Ye, H., Zhong, J., Xiang, S., et al. (2025) A Brain-to-Lung Signal from Gabaergic Neurons to ADRB2+ Interstitial Macrophages Promotes Pulmonary Inflammatory Responses. Immunity. [Google Scholar] [CrossRef] [PubMed]
[6] Chen, H., Zhou, X., Liu, T., Liu, J., Wu, D., Xu, X., et al. (2025) Postprandial Parasympathetic Signals Promote Lung Type 2 Immunity. Neuron, 113, 670-683.e7. [Google Scholar] [CrossRef] [PubMed]
[7] Jiang, Y., Yang, P., Yao, B., Zhang, L., Yang, M., Chen, Y., et al. (2025) Prophylactic and Therapeutic Itaconate Treatment Alleviates COVID-19-Associated Lung Injury. hLife. [Google Scholar] [CrossRef
[8] Xia, W., Mao, Y., Xia, Z., Cheng, J. and Jiang, P. (2025) Metabolic Remodelling Produces Fumarate via the Aspartate-Argininosuccinate Shunt in Macrophages as an Antiviral Defence. Nature Microbiology, 10, 1115-1129. [Google Scholar] [CrossRef] [PubMed]
[9] Tang, Y., Fu, X., Li, X., Fang, H., Yang, F., Wang, R., et al. (2025) Multi-Omics Analysis of Human Plasma Reveals Reprogramming of Tryptophan Metabolism Associated with Inflammation in Mycoplasma pneumoniae Pneumonia in Children. Journal of Infection, 91, Article ID: 106525. [Google Scholar] [CrossRef] [PubMed]
[10] Shi, Q., Zhang, P., Hu, Q., Zhang, T., Hou, R., Yin, S., et al. (2024) Role of TOMM34 on NF-κB Activation-Related Hyperinflammation in Severely Ill Patients with COVID-19 and Influenza. eBioMedicine, 108, Article ID: 105343. [Google Scholar] [CrossRef] [PubMed]
[11] Pirracchio, R., Venkatesh, B. and Legrand, M. (2024) Low-Dose Corticosteroids for Critically Ill Adults with Severe Pulmonary Infections. JAMA, 332, 318-328. [Google Scholar] [CrossRef] [PubMed]
[12] 瞿介明, 曹彬. 中国成人社区获得性肺炎诊断和治疗指南(2016年版) [J]. 中华结核和呼吸杂志, 2016, 39(4): 253-279.
[13] 陈丽萍, 陈军辉, 陈颖, 等. 糖皮质激素治疗社区获得性肺炎疗效及安全性Meta分析[J]. 中华急诊医学杂志, 2014, 23(1): 65-70.
[14] Rademaker, E., Haitsma Mulier, J.L.G., Drylewicz, J., Delemarre, E.M., Slim, M.A., Juffermans, N.P., et al. (2025) Immunomodulation for ARDS. CHEST Critical Care, 3, Article ID: 100129. [Google Scholar] [CrossRef
[15] 葛挺. 托珠单抗联合糖皮质激素在重型/危重型2019冠状病毒病中的应用效果[J]. 中国医学创新, 2024, 21(34): 93-97.
[16] 中华医学会呼吸病学分会, 中国抗癌协会肿瘤呼吸病专业委员会, 北京肿瘤防治研究会. 免疫检查点抑制剂相关肺炎诊治和管理专家共识(2025) [J]. 中华结核和呼吸杂志, 2025, 48(4): 329-343.
[17] Levy, J., DeAntonio, R. and Sáez-Llorens, X. (2025) Effectiveness of Pneumococcal Conjugate 13-Valent Vaccine against Severe Pneumonia in Panama: A Matched Case-Control Study. Jornal de Pediatria, 101, 601-607. [Google Scholar] [CrossRef] [PubMed]
[18] Shapira, S., Ben Shimon, M., Hay‐Levi, M., Shenberg, G., Choshen, G., Bannon, L., et al. (2022) A Novel Platform for Attenuating Immune Hyperactivity Using EXO‐CD24 in COVID‐19 and beyond. EMBO Molecular Medicine, 14, e15997. [Google Scholar] [CrossRef] [PubMed]